Navigation Links
Favrille in Medical News

New Report Just Published: World Multiple Myeloma Therapeutics Market Report

...g Agreement with Seattle Genetics II-51 Celgene Agrees to Acquisition of Pharmion II-51 PerkinElmer Plans Acquisition of ViaCell II-51 favrille Announces Acquisition of Monoclonal Antibody Range from Diversa II-52 Johnson & Johnson Secures Contract worth US$112 Million II-52 Bi...

MyMedicalRecords, Inc. and Favrille, Inc. Close Merger

... needs." "We believe that the combination of favrille and MMR offers our creditors and stockholders the ..." Merger Overview For legal purposes, favrille is acquiring MMR although the combination will be ...ses. As consideration in the business combination, favrille has issued (or reserved for issuance) 92,599,196 s...

Favrille and MyMedicalRecords.com, Inc. Announce Merger Agreement

...21LOGO ) "We believe that the proposed merger of favrille and MMR is consistent with our objective of offeri...ere in the world. We believe this transaction with favrille will give MMR broader access to the investment com...saction Under the terms of the merger agreement, favrille will acquire all of the capital stock of MMR, in a...

Favrille Announces Listing on OTC Bulletin Board

...le's filings with the Securities and Exchange Commission. All forward-looking statements are qualified in their entirety by this cautionary statement. favrille is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-l...

Favrille to Report New Data on FavId (Now Specifid) at American Society of Hematology Annual Meeting

.... About the Phase 3 Clinical Trial of Specifid favrille initiated a pivotal, double-blind, placebo control... from the U.S. Food and Drug Administration (FDA). favrille has also received Fast Track designation from the ...ed in their entirety by this cautionary statement. favrille is providing this information as of the date of th...
Favrille in Medical Technology

Favrille Announces Data Cutoff for Phase 3 Registration Trial of Specifid; Data Analysis and Unblinding Expected in June

...mation and prepare for the analysis and unblinding of the trial in June." favrille initiated its Phase 3 randomized, placebo-controlled, double-blind registra...ng statements are qualified in their entirety by this cautionary statement. favrille is providing this information as of the date of this release and, except as...

Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results

...Based in part on the guidance provided by the DMB, favrille has determined April 2008 to be the appropriate ti...se 3 trial." Third Quarter 2007 Financial Review favrille also reported its financial results for the third ...f 2008." Conference Call and Webcast Information favrille management will host a conference call today to di...

Favrille Announces Results From Study Showing Enhanced Activity From Insect Cell-Derived Immunotherapy for Lymphoma

...ient-specific, Id/KLH active immunotherapy for the treatment of B-cell NHL. favrille completed enrollment in its pivotal Phase 3 clinical trial of FavId followi...ng statements are qualified in their entirety by this cautionary statement. favrille is providing this information as of the date of this release and, except as...

Favrille Announces Data From Phase 2 Clinical Trial of FavId for Indolent B-Cell Non-Hodgkin's Lymphoma in Europe

...ient-specific, Id/KLH active immunotherapy for the treatment of B-cell NHL. favrille completed enrollment in its pivotal Phase 3 clinical trial of FavId followi...ng statements are qualified in their entirety by this cautionary statement. favrille is providing this information as of the date of this release and, except as...
Favrille in Biological Technology

Favrille and MyMedicalRecords.com, Inc. Obtain Shareholder Approval to Move Forward With Merger

...521LOGO ) "We are pleased to announce that favrille creditors holding more than 85% of the dollar valu...merger is subject to customary closing conditions, favrille meeting certain minimum cash requirements as of cl...and Where to Find It On November 13, 2008, favrille filed a Current Report on Form 8-K with the SEC th...

Favrille Announces Execution of Non-binding Term Sheet for a Merger Transaction

...on-binding term sheet for a reverse merger whereby favrille would acquire all of the capital stock of a privat...f MMR would own approximately 64% of the equity of favrille on a fully diluted basis. The existing equity holders of favrille would own approximately 29% of the Company. Approx...

Favrille Announces Receipt of Nasdaq Letters

...w the minimum $1.00 per share requirement and (ii) favrille has not maintained the $5,000,000 minimum market v...y. In accordance with Marketplace Rule 4450(e)(1), favrille has 90 calendar days, or until October 7, 2008, to...e with the minimum $1.00 per share requirement. If favrille does not regain compliance with either of the abov...

Favrille Announces Resolution of Debt Obligations and Plans for Maximizing Assets

...ll all unneeded fixed assets in the near future. favrille is currently in discussions with its landlord rega... options. The management and board of directors of favrille remain committed to addressing these issues and ma...ed in their entirety by this cautionary statement. favrille is providing this information as of the date of th...

Favrille Announces Workforce Reduction

...le's filings with the Securities and Exchange Commission. All forward-looking statements are qualified in their entirety by this cautionary statement. favrille is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-l...

Favrille Announces Results from Phase 3 Registration Trial of Specifid in Patients with Follicular B-Cell Non-Hodgkin's Lymphoma

...for their support and dedication." About the Phase 3 Registration Trial favrille initiated its Phase 3 randomized, placebo-controlled, double-blind registra...ng statements are qualified in their entirety by this cautionary statement. favrille is providing this information as of the date of this release and, except as...

Favrille Reports First Quarter 2008 Financial Results

...the first quarter of 2007. As of March 31, 2008, favrille had cash, cash equivalents and short-term investme...ng options." Phase 3 Registration Trial Update favrille reached the data cutoff date for its Phase 3 regis...trial. Conference Call and Webcast Information favrille management will host a conference call today to di...

Favrille Reports Fourth Quarter and Year End 2007 Financial Results

...e same periods in 2006. As of December 31, 2007, favrille had cash, cash equivalents and short-term investme...rille. Conference Call and Webcast Information favrille management will host a conference call today to di...ed in their entirety by this cautionary statement. favrille is providing this information as of the date of th...

Favrille Announces $21.1 Million Registered Direct Offering

...cal trials of longer duration in more patients are known. All forward-looking statements are qualified in their entirety by this cautionary statement. favrille is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-l...

Favrille to Present at BIO InvestorForum

...held at the Palace Hotel in San Francisco. (Logo: http://www.newscom.com/cgi-bin/prnh/20031013/LAM095LOGO ) Ms. Seymour will provide an overview of favrille and the clinical trials of its lead compound, FavId(R), which is currently in a pivotal Phase 3 clinical trial for the treatment of follicular B-cell ...
Other Tags
(Date:8/27/2014)... What’s next for 14 year old Sriram ... National Spelling Bee? Sririam will visit Philadelphia on Friday, ... Wills Eye Hospital.     , The teen from Painted Post, ... day. , Wills Eye Ophthalmologist-in-Chief, Dr. Julia Haller will ... visual diagnostic testing. He will also tour historic ...
(Date:8/27/2014)... Amy Norton HealthDay ... People who take part in clinical trials of new heart ... heart patient, a new study confirms. Experts said the ... the American Medical Association , aren,t surprising -- but they ... are enrolling a more select patient population that is not ...
(Date:8/27/2014)... August 27, 2014 Tejal K. Gandhi, MD, ... (NPSF) and the NPSF Lucian Leape Institute, is among ... August 25 issue of Modern Healthcare magazine. Also on the ... Andrew Sussman, MD, MBA; NPSF Lucian Leape Institute members ... who is a member of both the Institute and the ...
(Date:8/27/2014)... Silver Spring and Germantown, Md., and Denver (PRWEB) August ... healthcare real estate developer , has broken ground ... on the new Holy Cross Health hospital campus in ... of Bethesda, Md. Germantown is the third most populous ... medical office building on the Holy Cross Germantown Hospital ...
(Date:8/27/2014)... a parent wants to deal with, but it,s unfortunately ... old. , Skin that turns yellow can be a ... adequately eliminating the chemical bilirubin. But that discoloration is ... can harm a baby. , University of Washington engineers ... for jaundice in newborns and can deliver results to ...
Breaking Medicine News(10 mins):Health News:Scripps National Spelling Bee Co-Champion and Aspiring Ophthalmologist Coming to Wills Eye Hospital in Philadelphia 2Health News:Heart Studies Don't Reflect Real-World Patients, Study Finds 2Health News:Heart Studies Don't Reflect Real-World Patients, Study Finds 3Health News:NPSF President Among 100 Most Influential in Health Care 2Health News:NPSF President Among 100 Most Influential in Health Care 3Health News:NexCore Breaks Ground on Medical Office Building on Holy Cross Health Campus in Germantown, Maryland 2Health News:NexCore Breaks Ground on Medical Office Building on Holy Cross Health Campus in Germantown, Maryland 3Health News:NexCore Breaks Ground on Medical Office Building on Holy Cross Health Campus in Germantown, Maryland 4Health News:New smartphone app can detect newborn jaundice in minutes 2Health News:New smartphone app can detect newborn jaundice in minutes 3
(Date:8/27/2014)... but deadly disease that exists as five strains, none ... lethal strains is the Sudan ebolavirus (SUDV). Although not ... widespread illness, even as recently as 2012. In a ... Biology , researchers now report a possible therapy that ... John Dye, Sachdev Sidhu, Jonathan Lai and colleagues explain ...
(Date:8/27/2014)... that health advocates, campaigns against trans-fats have largely ... they,re taking aim at sugar for its potential ... policymakers are still wrangling over the best way ... to an article in Chemical & Engineering ... the American Chemical Society. , In the article, ...
(Date:8/27/2014)... Listeria is a dreaded bacterium that can be ... last few weeks, 28 persons in Denmark have been ... in supermarkets. 13 have died. , The bacterium is ... uncanny ability to adapt to changes in its surroundings, ... Together with colleagues from the Department of Biochemistry and ...
Breaking Biology News(10 mins):Potential therapy for the Sudan strain of Ebola could help contain some future outbreaks 2Researchers discover why Listeria bacterium is so hard to fight 2Researchers discover why Listeria bacterium is so hard to fight 3
Other Contents